Intellectual Property, Patents, USA The patentability of software in the US 12 November 2024 By Suzy Madar Read on
Australia, Intellectual Property, Patents, Technology Proposed modifications to the regulation of gene technology in Australia 4 November 2024 By Vicky Zhang, Suzy Madar, Damien MacRae Read on
Global, Intellectual Property, Patents, Technology The mRNA patent wars: lessons for businesses & organisations who rely on patent rights 28 October 2024 By Damien MacRae, Suzy Madar Read on
Copyright, Intellectual Property, Patents, Trade marks IPO 2018: Insights from the USPTO, EPO and the bench (when digital natives meet digital immigrants) 28 September 2018 By Suzy Madar Read on
Intellectual Property, Patents United States FDA gets serious about biosimilars 5 September 2018 By Suzy Madar Read on
Intellectual Property, Patents Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China 27 April 2018 By Suzy Madar Read on
Intellectual Property, Patents Second throw of the dice unsuccessful: Full Federal Court confirms Hepatitis C drug patent is invalid 21 December 2017 By Suzy Madar Read on
Intellectual Property Biosimilars: balancing access to affordable medicines with safety 3 November 2017 By Suzy Madar Read on
Intellectual Property, Patents Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent) 26 August 2016 By Suzy Madar Read on
Intellectual Property Next steps after Australia China Free Trade Agreement – how to make the most of the opportunity 23 July 2015 By Suzy Madar Read on
